PDB Short entry for 2IW9 HEADER CELL CYCLE 27-JUN-06 2IW9 TITLE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A TITLE 2 BISANILINOPYRIMIDINE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: CYCLIN DEPENDENT KINASE 2, P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 OTHER_DETAILS: PHOSPHOTHREONINE 160; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: CYCLIN-A2; COMPND 11 CHAIN: B, D; COMPND 12 FRAGMENT: A3, RESIDUES 174-432; COMPND 13 SYNONYM: HUMAN CYCLIN A, CYCLIN-A; COMPND 14 ENGINEERED: YES; COMPND 15 OTHER_DETAILS: MONOTHIOGLYCEROL ADDUCT ON RESIDUE 193 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PGEX 6P-1; SOURCE 10 OTHER_DETAILS: WILD TYPE GENE WAS A GIFT FROM DR D.O.MORGAN; SOURCE 11 MOL_ID: 2; SOURCE 12 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 13 ORGANISM_COMMON: HUMAN; SOURCE 14 ORGANISM_TAXID: 9606; SOURCE 15 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 16 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 17 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 18 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 19 EXPRESSION_SYSTEM_PLASMID: PET21D; SOURCE 20 OTHER_DETAILS: FULL LENGTH CYCLIN A WAS A GIFT FROM DR M.DOREE KEYWDS PHOSPHORYLATION, NUCLEOTIDE-BINDING, SERINE/THREONINE-PROTEIN KINASE, KEYWDS 2 CELL CYCLE COMPLEX, KINASE, MITOSIS, CELL CYCLE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR D.J.PRATT,J.BENTLEY,P.JEWSBURY,F.T.BOYLE,J.A.ENDICOTT,M.E.M.NOBLE REVDAT 4 13-DEC-23 2IW9 1 LINK REVDAT 3 13-JUL-11 2IW9 1 VERSN REVDAT 2 24-FEB-09 2IW9 1 VERSN REVDAT 1 06-SEP-06 2IW9 0 JRNL AUTH D.J.PRATT,J.BENTLEY,P.JEWSBURY,F.T.BOYLE,J.A.ENDICOTT, JRNL AUTH 2 M.E.M.NOBLE JRNL TITL DISSECTING THE DETERMINANTS OF CYCLIN-DEPENDENT KINASE 2 AND JRNL TITL 2 CYCLIN-DEPENDENT KINASE 4 INHIBITOR SELECTIVITY. JRNL REF J.MED.CHEM. V. 49 5470 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16942020 JRNL DOI 10.1021/JM060216X REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 100.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 97.6 REMARK 3 NUMBER OF REFLECTIONS : 92560 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.212 REMARK 3 R VALUE (WORKING SET) : 0.210 REMARK 3 FREE R VALUE : 0.240 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 4861 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.05 REMARK 3 REFLECTION IN BIN (WORKING SET) : 6597 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2430 REMARK 3 BIN FREE R VALUE SET COUNT : 355 REMARK 3 BIN FREE R VALUE : 0.2830 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8640 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 70 REMARK 3 SOLVENT ATOMS : 384 REMARK 3 REMARK 3 B VALUES. REMARK 3 B VALUE TYPE : LIKELY RESIDUAL REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 36.51 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.00000 REMARK 3 B22 (A**2) : 1.49000 REMARK 3 B33 (A**2) : -0.49000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.174 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.155 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.112 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 7.880 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.946 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.930 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 8985 ; 0.012 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12199 ; 1.294 ; 1.985 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1066 ; 5.554 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 388 ;40.540 ;23.866 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1587 ;15.047 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 45 ;18.675 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1391 ; 0.090 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 6623 ; 0.005 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 4226 ; 0.195 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 6088 ; 0.302 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 457 ; 0.175 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 60 ; 0.155 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 13 ; 0.262 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5572 ; 0.640 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 8764 ; 1.010 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3913 ; 1.666 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3435 ; 2.502 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 2 REMARK 3 REMARK 3 NCS GROUP NUMBER : 1 REMARK 3 CHAIN NAMES : A C REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 A 0 A 298 4 REMARK 3 1 C 0 C 298 4 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 MEDIUM POSITIONAL 1 A (A): 2102 ; .42 ; .50 REMARK 3 MEDIUM POSITIONAL 1 C (A): 2102 ; .42 ; .50 REMARK 3 MEDIUM THERMAL 1 A (A**2): 2102 ; .83 ; 2.00 REMARK 3 MEDIUM THERMAL 1 C (A**2): 2102 ; .83 ; 2.00 REMARK 3 REMARK 3 NCS GROUP NUMBER : 2 REMARK 3 CHAIN NAMES : B D REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 B 175 B 432 4 REMARK 3 1 D 175 D 432 4 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 MEDIUM POSITIONAL 2 B (A): 2022 ; .28 ; .50 REMARK 3 MEDIUM POSITIONAL 2 D (A): 2022 ; .28 ; .50 REMARK 3 MEDIUM THERMAL 2 B (A**2): 2022 ; .65 ; 2.00 REMARK 3 MEDIUM THERMAL 2 D (A**2): 2022 ; .65 ; 2.00 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 4 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 2 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 0 A 298 REMARK 3 RESIDUE RANGE : A 1298 A 1298 REMARK 3 ORIGIN FOR THE GROUP (A): 6.7580 40.5630 64.3110 REMARK 3 T TENSOR REMARK 3 T11: -.2753 T22: -.2022 REMARK 3 T33: -.1555 T12: .0219 REMARK 3 T13: -.0327 T23: .0153 REMARK 3 L TENSOR REMARK 3 L11: 1.7485 L22: 1.3345 REMARK 3 L33: 1.7242 L12: .4200 REMARK 3 L13: -.7125 L23: -.2938 REMARK 3 S TENSOR REMARK 3 S11: .0643 S12: .0597 S13: .0008 REMARK 3 S21: -.1367 S22: .0064 S23: .1145 REMARK 3 S31: -.0738 S32: -.1446 S33: -.0706 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : B 175 B 432 REMARK 3 ORIGIN FOR THE GROUP (A): 21.9120 67.3040 77.5070 REMARK 3 T TENSOR REMARK 3 T11: -.1594 T22: -.1972 REMARK 3 T33: -.1574 T12: -.0027 REMARK 3 T13: .0573 T23: -.0548 REMARK 3 L TENSOR REMARK 3 L11: 1.5443 L22: 1.8670 REMARK 3 L33: 1.8045 L12: -.2853 REMARK 3 L13: .5958 L23: -.1941 REMARK 3 S TENSOR REMARK 3 S11: -.0450 S12: -.1627 S13: .1227 REMARK 3 S21: .0842 S22: .1082 S23: -.0520 REMARK 3 S31: -.2787 S32: -.0123 S33: -.0632 REMARK 3 REMARK 3 TLS GROUP : 3 REMARK 3 NUMBER OF COMPONENTS GROUP : 2 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : C 0 C 298 REMARK 3 RESIDUE RANGE : C 1297 C 1297 REMARK 3 ORIGIN FOR THE GROUP (A): 44.6190 81.0550 42.6270 REMARK 3 T TENSOR REMARK 3 T11: .0458 T22: .1259 REMARK 3 T33: -.0880 T12: -.1345 REMARK 3 T13: -.0870 T23: .1553 REMARK 3 L TENSOR REMARK 3 L11: 1.5483 L22: 2.0641 REMARK 3 L33: 1.3173 L12: .4819 REMARK 3 L13: -.8352 L23: -.4619 REMARK 3 S TENSOR REMARK 3 S11: .1651 S12: -.0338 S13: .0639 REMARK 3 S21: .2860 S22: -.2618 S23: -.2037 REMARK 3 S31: -.2799 S32: .4046 S33: .0967 REMARK 3 REMARK 3 TLS GROUP : 4 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : D 175 D 432 REMARK 3 ORIGIN FOR THE GROUP (A): 44.9980 47.8090 39.0750 REMARK 3 T TENSOR REMARK 3 T11: -.0177 T22: .1110 REMARK 3 T33: .0897 T12: .2115 REMARK 3 T13: -.0108 T23: .1024 REMARK 3 L TENSOR REMARK 3 L11: 3.3482 L22: 2.8461 REMARK 3 L33: 1.9097 L12: .6779 REMARK 3 L13: .5652 L23: -1.0776 REMARK 3 S TENSOR REMARK 3 S11: .1363 S12: .2167 S13: -.5541 REMARK 3 S21: -.0047 S22: -.3747 S23: -.7307 REMARK 3 S31: .2759 S32: .6418 S33: .2384 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2IW9 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 27-JUN-06. REMARK 100 THE DEPOSITION ID IS D_1290029200. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 23-NOV-02 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 97458 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 47.100 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.1 REMARK 200 DATA REDUNDANCY : 2.600 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 6.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.10 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.7 REMARK 200 DATA REDUNDANCY IN SHELL : 2.50 REMARK 200 R MERGE FOR SHELL (I) : 0.35000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1H1S REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 56.62 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.86 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE DROPLET CONTAINED PROTEIN AT A REMARK 280 CONCENTRATION OF 10 MG ML-1 IN 40 MM HEPES PH 7.0 CONTAINING 1 REMARK 280 MM DTT, 200 MM NACL, 5% V/V DMSO AND 1MM INHIBITOR. THE REMARK 280 RESERVOIR SOLUTION CONTAINED 0.8 M KCL AND 1.2 M (NH4)2SO4 IN 40 REMARK 280 MM HEPES PH 7.0 AND 5 MM DTT, PH 7.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 36.87900 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 74.06000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 67.05000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 74.06000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 36.87900 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 67.05000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4340 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 22230 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4140 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 22960 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -27.9 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, LYS 89 TO THR REMARK 400 ENGINEERED RESIDUE IN CHAIN C, LYS 89 TO THR REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -3 REMARK 465 PRO A -2 REMARK 465 GLY A -1 REMARK 465 ASP A 38 REMARK 465 THR A 39 REMARK 465 GLU A 40 REMARK 465 THR A 41 REMARK 465 LEU A 298 REMARK 465 MET B 173 REMARK 465 GLU B 174 REMARK 465 VAL B 175 REMARK 465 ASP B 283 REMARK 465 ASP B 284 REMARK 465 GLY C -3 REMARK 465 PRO C -2 REMARK 465 GLY C -1 REMARK 465 ASP C 223 REMARK 465 GLU C 224 REMARK 465 VAL C 225 REMARK 465 VAL C 226 REMARK 465 TRP C 227 REMARK 465 PRO C 228 REMARK 465 GLY C 229 REMARK 465 VAL C 230 REMARK 465 THR C 231 REMARK 465 SER C 232 REMARK 465 MET C 233 REMARK 465 PRO C 234 REMARK 465 ASP C 235 REMARK 465 TYR C 236 REMARK 465 LYS C 237 REMARK 465 PRO C 238 REMARK 465 SER C 239 REMARK 465 PHE C 240 REMARK 465 PRO C 241 REMARK 465 LYS C 242 REMARK 465 TRP C 243 REMARK 465 ALA C 244 REMARK 465 ARG C 245 REMARK 465 GLN C 246 REMARK 465 ASP C 247 REMARK 465 PHE C 248 REMARK 465 SER C 249 REMARK 465 LYS C 250 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 MET D 173 REMARK 465 GLU D 174 REMARK 465 VAL D 175 REMARK 465 PRO D 176 REMARK 465 ASP D 177 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2091 O HOH B 2051 2.03 REMARK 500 O HOH A 2021 O HOH A 2022 2.07 REMARK 500 O GLY C 220 OH TYR C 269 2.08 REMARK 500 OG SER A 181 O HOH A 2103 2.14 REMARK 500 SG CYS B 193 S1 SGM B 1433 2.16 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 GLU D 374 CD GLU D 374 OE1 0.202 REMARK 500 GLU D 374 CD GLU D 374 OE2 0.199 REMARK 500 GLN D 403 CD GLN D 403 OE1 0.148 REMARK 500 THR D 429 C THR D 429 O 0.253 REMARK 500 THR D 429 C LEU D 430 N 0.194 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 GLU D 374 OE1 - CD - OE2 ANGL. DEV. = 11.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 127 41.42 -155.26 REMARK 500 ASP A 145 78.45 50.41 REMARK 500 VAL A 164 127.63 69.51 REMARK 500 SER A 181 -144.01 -148.12 REMARK 500 ASP B 177 -156.03 179.15 REMARK 500 TYR B 178 5.28 55.57 REMARK 500 TRP B 372 111.84 -28.62 REMARK 500 THR C 41 -81.51 -128.16 REMARK 500 ASP C 127 39.87 -146.86 REMARK 500 ASP C 145 77.69 46.09 REMARK 500 VAL C 164 132.13 66.28 REMARK 500 SER C 181 -146.35 -150.87 REMARK 500 THR C 290 -166.79 -119.17 REMARK 500 TRP D 372 113.29 -31.35 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 PRO B 176 ASP B 177 141.25 REMARK 500 ASP B 177 TYR B 178 -140.22 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 THR D 429 -12.59 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH B2001 DISTANCE = 6.52 ANGSTROMS REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG B1434 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 MET B 200 O REMARK 620 2 GLN B 203 O 83.8 REMARK 620 3 ILE B 206 O 114.6 99.8 REMARK 620 4 HOH B2023 O 166.7 88.2 77.2 REMARK 620 N 1 2 3 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG D1434 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 MET D 200 O REMARK 620 2 GLN D 203 O 91.5 REMARK 620 3 ILE D 206 O 106.3 94.9 REMARK 620 4 HOH D2007 O 84.7 165.3 99.8 REMARK 620 N 1 2 3 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MG B1434 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MG D1434 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 4SP A1298 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 4SP C1297 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SGM B1433 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SGM D1433 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9- REMARK 900 TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5T RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, REMARK 900 CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 999 REMARK 999 SEQUENCE REMARK 999 GPGS INTRODUCED AT N-TERMINUS BY CLONING. REMARK 999 M INTRODUCED AT N-TERMINUS BY CLONING. DBREF 2IW9 A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2IW9 B 174 432 UNP P20248 CCNA2_HUMAN 174 432 DBREF 2IW9 C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2IW9 D 174 432 UNP P20248 CCNA2_HUMAN 174 432 SEQADV 2IW9 GLY A -3 UNP P24941 EXPRESSION TAG SEQADV 2IW9 PRO A -2 UNP P24941 EXPRESSION TAG SEQADV 2IW9 GLY A -1 UNP P24941 EXPRESSION TAG SEQADV 2IW9 SER A 0 UNP P24941 EXPRESSION TAG SEQADV 2IW9 THR A 89 UNP P24941 LYS 89 ENGINEERED MUTATION SEQADV 2IW9 MET B 173 UNP P20248 EXPRESSION TAG SEQADV 2IW9 GLY C -3 UNP P24941 EXPRESSION TAG SEQADV 2IW9 PRO C -2 UNP P24941 EXPRESSION TAG SEQADV 2IW9 GLY C -1 UNP P24941 EXPRESSION TAG SEQADV 2IW9 SER C 0 UNP P24941 EXPRESSION TAG SEQADV 2IW9 THR C 89 UNP P24941 LYS 89 ENGINEERED MUTATION SEQADV 2IW9 MET D 173 UNP P20248 EXPRESSION TAG SEQRES 1 A 302 GLY PRO GLY SER MET GLU ASN PHE GLN LYS VAL GLU LYS SEQRES 2 A 302 ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA ARG SEQRES 3 A 302 ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS ILE SEQRES 4 A 302 ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR ALA SEQRES 5 A 302 ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS PRO SEQRES 6 A 302 ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU ASN SEQRES 7 A 302 LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU SEQRES 8 A 302 LYS THR PHE MET ASP ALA SER ALA LEU THR GLY ILE PRO SEQRES 9 A 302 LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU GLN SEQRES 10 A 302 GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS ARG SEQRES 11 A 302 ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU GLY SEQRES 12 A 302 ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE SEQRES 13 A 302 GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL THR SEQRES 14 A 302 LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS SEQRES 15 A 302 TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY CYS SEQRES 16 A 302 ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE PRO SEQRES 17 A 302 GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG SEQRES 18 A 302 THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY VAL SEQRES 19 A 302 THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS TRP SEQRES 20 A 302 ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU ASP SEQRES 21 A 302 GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS TYR SEQRES 22 A 302 ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU ALA SEQRES 23 A 302 HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO HIS SEQRES 24 A 302 LEU ARG LEU SEQRES 1 B 260 MET GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 B 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 B 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 B 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 B 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 B 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 B 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 B 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 B 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 B 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 B 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 B 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 B 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 B 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 B 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 B 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 B 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 B 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 B 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 B 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 302 GLY PRO GLY SER MET GLU ASN PHE GLN LYS VAL GLU LYS SEQRES 2 C 302 ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA ARG SEQRES 3 C 302 ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS ILE SEQRES 4 C 302 ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR ALA SEQRES 5 C 302 ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS PRO SEQRES 6 C 302 ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU ASN SEQRES 7 C 302 LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU SEQRES 8 C 302 LYS THR PHE MET ASP ALA SER ALA LEU THR GLY ILE PRO SEQRES 9 C 302 LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU GLN SEQRES 10 C 302 GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS ARG SEQRES 11 C 302 ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU GLY SEQRES 12 C 302 ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE SEQRES 13 C 302 GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL THR SEQRES 14 C 302 LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS SEQRES 15 C 302 TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY CYS SEQRES 16 C 302 ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE PRO SEQRES 17 C 302 GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG SEQRES 18 C 302 THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY VAL SEQRES 19 C 302 THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS TRP SEQRES 20 C 302 ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU ASP SEQRES 21 C 302 GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS TYR SEQRES 22 C 302 ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU ALA SEQRES 23 C 302 HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO HIS SEQRES 24 C 302 LEU ARG LEU SEQRES 1 D 260 MET GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 D 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 D 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 D 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 D 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 D 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 D 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 D 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 D 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 D 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 D 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 D 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 D 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 D 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 D 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 D 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 D 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 D 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 D 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 D 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU MODRES 2IW9 TPO A 160 THR PHOSPHOTHREONINE MODRES 2IW9 TPO C 160 THR PHOSPHOTHREONINE HET TPO A 160 11 HET TPO C 160 11 HET 4SP A1298 28 HET SGM B1433 6 HET MG B1434 1 HET 4SP C1297 28 HET SGM D1433 6 HET MG D1434 1 HETNAM TPO PHOSPHOTHREONINE HETNAM 4SP O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE HETNAM SGM MONOTHIOGLYCEROL HETNAM MG MAGNESIUM ION HETSYN TPO PHOSPHONOTHREONINE FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 5 4SP 2(C18 H22 N6 O3 S) FORMUL 6 SGM 2(C3 H8 O2 S) FORMUL 7 MG 2(MG 2+) FORMUL 11 HOH *384(H2 O) HELIX 1 1 SER A 0 GLU A 2 5 3 HELIX 2 2 PRO A 45 LEU A 58 1 14 HELIX 3 3 LEU A 87 SER A 94 1 8 HELIX 4 4 PRO A 100 HIS A 121 1 22 HELIX 5 5 LYS A 129 GLN A 131 5 3 HELIX 6 6 THR A 165 ARG A 169 5 5 HELIX 7 7 ALA A 170 LEU A 175 1 6 HELIX 8 8 THR A 182 ARG A 199 1 18 HELIX 9 9 SER A 207 GLY A 220 1 14 HELIX 10 10 GLY A 229 MET A 233 5 5 HELIX 11 11 ASP A 247 VAL A 252 1 6 HELIX 12 12 ASP A 256 LEU A 267 1 12 HELIX 13 13 SER A 276 LEU A 281 1 6 HELIX 14 14 ALA A 282 GLN A 287 5 6 HELIX 15 15 TYR B 178 CYS B 193 1 16 HELIX 16 16 GLY B 198 GLN B 203 5 6 HELIX 17 17 THR B 207 TYR B 225 1 19 HELIX 18 18 GLN B 228 SER B 244 1 17 HELIX 19 19 LEU B 249 GLY B 251 5 3 HELIX 20 20 LYS B 252 GLU B 269 1 18 HELIX 21 21 GLU B 274 THR B 282 1 9 HELIX 22 22 THR B 287 LEU B 302 1 16 HELIX 23 23 THR B 310 LEU B 320 1 11 HELIX 24 24 ASN B 326 ASP B 343 1 18 HELIX 25 25 ASP B 343 LEU B 348 1 6 HELIX 26 26 LEU B 351 GLY B 369 1 19 HELIX 27 27 PRO B 373 GLY B 381 1 9 HELIX 28 28 THR B 383 ALA B 401 1 19 HELIX 29 29 PRO B 402 HIS B 404 5 3 HELIX 30 30 GLN B 407 TYR B 413 1 7 HELIX 31 31 LYS B 414 HIS B 419 5 6 HELIX 32 32 GLY B 420 LEU B 424 5 5 HELIX 33 33 PRO C 45 LYS C 56 1 12 HELIX 34 34 LEU C 87 SER C 94 1 8 HELIX 35 35 PRO C 100 HIS C 121 1 22 HELIX 36 36 ASP C 145 ALA C 149 5 5 HELIX 37 37 THR C 165 ARG C 169 5 5 HELIX 38 38 ALA C 170 LEU C 175 1 6 HELIX 39 39 THR C 182 ARG C 199 1 18 HELIX 40 40 SER C 207 GLY C 220 1 14 HELIX 41 41 ASP C 256 LEU C 267 1 12 HELIX 42 42 SER C 276 ALA C 282 1 7 HELIX 43 43 HIS C 283 GLN C 287 5 5 HELIX 44 44 TYR D 178 CYS D 193 1 16 HELIX 45 45 GLY D 198 GLN D 203 5 6 HELIX 46 46 THR D 207 TYR D 225 1 19 HELIX 47 47 GLN D 228 MET D 246 1 19 HELIX 48 48 LEU D 249 GLY D 251 5 3 HELIX 49 49 LYS D 252 GLU D 269 1 18 HELIX 50 50 GLU D 274 THR D 282 1 9 HELIX 51 51 THR D 287 LEU D 302 1 16 HELIX 52 52 THR D 310 PHE D 319 1 10 HELIX 53 53 LEU D 320 GLN D 322 5 3 HELIX 54 54 ASN D 326 ASP D 343 1 18 HELIX 55 55 ASP D 343 LEU D 348 1 6 HELIX 56 56 LEU D 351 THR D 368 1 18 HELIX 57 57 PRO D 373 GLY D 381 1 9 HELIX 58 58 LEU D 387 LYS D 400 1 14 HELIX 59 59 ALA D 401 HIS D 404 5 4 HELIX 60 60 GLN D 407 TYR D 413 1 7 HELIX 61 61 LYS D 414 HIS D 419 5 6 HELIX 62 62 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLY A 11 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 11 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK C TYR A 159 N TPO A 160 1555 1555 1.33 LINK C TPO A 160 N HIS A 161 1555 1555 1.33 LINK C TYR C 159 N TPO C 160 1555 1555 1.33 LINK C TPO C 160 N HIS C 161 1555 1555 1.33 LINK O MET B 200 MG MG B1434 1555 1555 2.74 LINK O GLN B 203 MG MG B1434 1555 1555 2.33 LINK O ILE B 206 MG MG B1434 1555 1555 2.31 LINK MG MG B1434 O HOH B2023 1555 1555 2.50 LINK O MET D 200 MG MG D1434 1555 1555 2.45 LINK O GLN D 203 MG MG D1434 1555 1555 2.18 LINK O ILE D 206 MG MG D1434 1555 1555 2.44 LINK MG MG D1434 O HOH D2007 1555 1555 2.56 CISPEP 1 VAL A 154 PRO A 155 0 -7.93 CISPEP 2 GLN B 323 PRO B 324 0 -10.46 CISPEP 3 ASP B 345 PRO B 346 0 8.40 CISPEP 4 VAL C 154 PRO C 155 0 -3.94 CISPEP 5 GLN D 323 PRO D 324 0 -2.14 CISPEP 6 ASP D 345 PRO D 346 0 9.13 SITE 1 AC1 4 MET B 200 GLN B 203 ILE B 206 HOH B2023 SITE 1 AC2 4 MET D 200 GLN D 203 ILE D 206 HOH D2007 SITE 1 AC3 14 ILE A 10 GLU A 12 ALA A 31 VAL A 64 SITE 2 AC3 14 PHE A 80 GLU A 81 LEU A 83 HIS A 84 SITE 3 AC3 14 GLN A 85 ASP A 86 THR A 89 ASN A 132 SITE 4 AC3 14 LEU A 134 HOH A2171 SITE 1 AC4 16 ILE C 10 GLU C 12 VAL C 18 ALA C 31 SITE 2 AC4 16 VAL C 64 PHE C 80 GLU C 81 PHE C 82 SITE 3 AC4 16 LEU C 83 HIS C 84 GLN C 85 ASP C 86 SITE 4 AC4 16 THR C 89 ASN C 132 LEU C 134 HOH C2049 SITE 1 AC5 5 MET B 189 LYS B 192 CYS B 193 ARG B 241 SITE 2 AC5 5 ASP B 305 SITE 1 AC6 4 MET D 189 LYS D 192 CYS D 193 ARG D 241 CRYST1 73.758 134.100 148.120 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013558 0.000000 0.000000 0.00000 SCALE2 0.000000 0.007457 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006751 0.00000